GlassScriptPhysician profile
Gregory Trubowitsch
NPI 1821091182
$7,783.86
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $947 · 2021: $2,676 · 2022: $2,323.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $5,992.47 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $500.42 | 2019-2021 | |
| Allergan, INC. | $319.03 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $260.85 | 2021 | |
| Alcon Vision LLC | $221.50 | 2019-2021 | |
| Eyepoint US, INC. | $167.79 | 2019 | |
| Alimera Sciences, INC. | $121.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $100.40 | 2019 | |
| Genentech USA, INC. | $99.56 | 2019 |
Research and ownership
$196,166.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Trubowitsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.